# US 2013/0296363 A1 · Quinoline and isoquinoline derivatives for use as jak modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296363 A1
- Document ID: US20130296363A1
- Status: Published application
- Kind: A1
- Application number: 13/819,283
- Filed: 2011-08-31
- Published: 2013-11-07
- Earliest claimed: 2010-09-01
- Assignees: Ambit Biosciences Corporation
- Inventors: Raffaella Faraoni; Michael J. Hadd; Mark W. Holladay; Martin W. Rowbottom; Eduardo Setti
- Web page: https://patentgrep.com/patent/US20130296363A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

## Claims

### Claim 1

A compound having formula (I):
or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein
Z1 and Z2 are each independently N or CR0, such that one of Z1 or Z2 is N and the other is CR0;
ring A is azolyl;
ring B is aryl or heteroaryl;
Y is a linker selected from —C(R1)(R2)—, —S(O)— and —S(O)2—;
R0 is hydrogen, cyano or alkyl;
R1 and R2 are selected from (i), (ii), (iii), (iv) and (v) as follows:
(i) R1 and R2 together form ═O, ═S, ═NR9 or ═CR10R11;
(ii) R1 and R2 are both —OR8, or R1 and R2, together with the carbon atom to which they are attached, form cycloalkyl or heterocyclyl wherein the cycloalkyl is substituted with one to four substituents selected from halo, deutero, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cyano, ═O, ═N—OR21, —RxOR21, —RxN(R22)2, —RxS(O)qR23, —C(O)R21, —C(O)OR21 and —C(O)N(R22)2, and wherein the heterocyclyl contains one to two heteroatoms selected from O, NR24, S, S(O) and S(O)2;
(iii) R1 is hydrogen or halo; and R2 is halo;
(iv) R1 is alkyl, alkenyl, alkynyl, cycloalkyl or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and aryl are each optionally substituted with one to four substitutents selected from halo, cyano, alkyl, —RxORw, —RxS(O)qRv, —RxNRyRz and —C(O)ORw; and R2 is hydrogen, halo or —ORs; and
(v) R1 is halo, deutero, —OR12, —NR13R14, or —S(O)qR15; and R2 is hydrogen, deutero, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and aryl are each optionally substituted with one to four substitutents selected from halo, cyano, alkyl, —RxORw, —RxS(O)qRv and —RxNRyRz;
R3 is hydrogen, deutero, halo, alkyl, cyano, haloalkyl, deuteroalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R5 is hydrogen or alkyl;
each R6 is independently selected from deutero, halo, nitro, cyano, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz, —RxS(O)qRv, —RxNR19C(O)R8, —RxC(O)OR18 and —RxNR19S(O)qRv; where the alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one, two or three halo, oxo, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl groups;
each R7 is independently halo, alkyl, haloalkyl or —RxORw;
R8 is alkyl, alkenyl or alkynyl;
R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or amino;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, haloalkyl or —C(O)OR8;
R12 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)Rv, —C(O)ORw and —C(O)NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one to four substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl; and R14 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, —C(O)Rv, —C(O)ORw, —C(O)NRyRz and —S(O)qRv, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one to four substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl or heteroaryl wherein the heterocyclyl and heteroaryl are substituted with one to four substituents independently selected from halo, alkyl, hydroxy, alkoxy, amino and alkylthio, and wherein the heterocyclyl is optionally substituted with oxo;
R15 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)NRyRz or —NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one to four substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R18 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; wherein R18 is optionally substituted with 1 to 3 groups Q1, each Q1 independently selected from alkyl, hydroxy, halo, haloalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, carboxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloaryl and amino;
R19 and R20 are selected as follows:
(i) R19 and R20 are each independently hydrogen or alkyl; or
(ii) R19 and R20, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which are each optionally substituted with 1 to 2 groups each independently selected from halo, oxo, alkyl, haloalkyl, hydroxyl and alkoxy;
R21 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl;
each R22 is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl; or both R22, together with the nitrogen atom to which they are attached, form a heterocyclyl optionally substituted with oxo;
R23 is alkyl, alkenyl, alkynyl or haloalkyl;
R24 is hydrogen or alkyl;
each Rx is independently alkylene or a direct bond;
Rv is hydrogen, alkyl, alkenyl or alkynyl;
Rw is independently hydrogen, alkyl, alkenyl, alkynyl or haloalkyl;
Ry and Rz are selected as follows:
(i) Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl or heterocyclyl;
(ii) Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which are optionally substituted with 1 to 2 groups each independently selected from halo, alkyl, haloalkyl, hydroxyl and alkoxy;
n is 0-4;
p is 0-5;
each q is independently 0, 1 or 2; and
r is 1-3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein p is 1 or 2.

### Claim 3 (depends on 1)

The compound of claim 1 having formula (II)
or a pharmaceutically acceptable salt, solvate or hydrate thereof, A1 and A1 are CH, and p is 1 or 2.

### Claim 4 (depends on 1)

The compound of claim 1 having formula (IIIa) or (IIIb)
or a pharmaceutically acceptable salt, solvate or hydrate thereof, where
A1 and A2 are each independently selected from N and CH;
A is azolyl;
Y is a linker selected from —C(R1)(R2)—, —S(O)— and —S(O)2—;
R0 is hydrogen, cyano or alkyl;
R1 and R2 are selected as follows:
(i) R1 and R2 together form ═O;
(ii) R1 is hydrogen or halo; and R2 is halo;
(iii) R1 is alkyl, and R2 is hydrogen, alkyl, halo, hydroxy or alkoxy; or
(iv) R1 is halo, NR13R14, hydroxy or alkoxy; and R2 is hydrogen or alkyl;
R3 is hydrogen, halo, alkyl, deuteroalkyl, hydroxy or alkoxy;
R5 is hydrogen or alkyl;
R13 is hydrogen or alkyl;
R14 is hydrogen, alkyl or cycloalkyl;
each R6 is independently deutero, halo or alkyl;
R7 halo;
n is 0 or 1;
p is 1; and
r is 1-3.

### Claim 5 (depends on 1)

The compound of claim 1 having formula (Va) or (Vb)
or a pharmaceutically acceptable salt, solvate or hydrate thereof, where
A is pyrazolyl, imidazolyl, oxazolyl or thiazolyl;
Y is a linker selected from —C(R1)(R2)—, —S(O)— and —S(O)2—;
R0 is hydrogen, cyano or alkyl;
R1 and R2 are selected as follows:
(i) R1 and R2 together form ═O;
(ii) R1 is hydrogen or halo; and R2 is halo;
(iii) R1 is alkyl, and R2 is hydrogen, alkyl, halo, hydroxy or alkoxy; or
(iv) R1 is halo, NR13R14, hydroxy or alkoxy; and R2 is hydrogen or alkyl;
R3 is hydrogen, halo, alkyl, deuteroalkyl, hydroxy or alkoxy;
R5 is hydrogen or alkyl;
R13 is hydrogen or alkyl;
R14 is hydrogen, alkyl or cycloalkyl;
R7 halo; and
r is 1-3.

### Claim 6 (depends on 1)

The compound of claim 1, wherein A is pyrazolyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, or triazolyl, and p is 1 or 2.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Y is —S(O)2—, and p is 1 or 2.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R7 is halo, and p is 1 or 2.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R7 is fluoro, and p is 1 or 2.

### Claim 10 (depends on 2)

The compound of claim 2 having formula ((VIIa) or (VIIb):
or a pharmaceutically acceptable salt, solvate or hydrate thereof, where
X1, X2 and X3 are selected from (i) and (ii) as follows
(i) X1 is NR4, X2 is CR3 and X3 is CH; and
(ii) X1 is CH, X2 is CR3 and X3 is S;
R3 is hydrogen or alkyl;
R4 is hydrogen or alkyl;
R6 is deutero, halo or alkyl;
R7 is deutero, halo or alkyl and
p is 1 or 2.

### Claim 11 (depends on 10)

The compound of claim 10, wherein X1 is NR4, X2 is CR3 and X3 is CH.

### Claim 12 (depends on 1)

The compound of claim 1, wherein each R3 is independently hydrogen, halo, alkyl, deuteroalkyl, hydroxy or alkoxy.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R0 is hydrogen.

### Claim 14 (depends on 1)

The compound of claim 1 selected from:
3-((4-fluorophenyl)sulfinyl)-N-(5-methyl-H-pyrazol-3-yl)isoquinolin-1-amine;
(4-fluorophenyl)(1-((5-methyl-1H-pyrazol-3-yl)amino)isoquinolin-3-yl)methanone;
(4-fluorophenyl)(1-((5-methyl-1H-pyrazol-3-yl)amino)isoquinolin-3-yl)methanol;
N-(3-((4-fluorophenyl)sulfinyl)isoquinolin-1-yl)thiazol-2-amine;
N-(3-((4-fluorophenyl)sulfinyl)isoquinolin-1-yl)-5-methylthiazol-2-amine;
N-(3-((4-fluorophenyl)sulfinyl)isoquinolin-1-yl)-4-methyloxazol-2-amine;
3-((4-fluorophenyl)sulfinyl)-N-(4-methoxypyridin-2-yl)isoquinolin-1-amine;
(4-fluorophenyl)(4-(4-fluorophenyl)-1-((5-methyl-1H-pyrazol-3-yl)amino)isoquinolin-3-yl)methanone;
(4-fluorophenyl)(4-(4-fluorophenyl)-1-((5-methyl-1H-pyrazol-3-yl)amino)isoquinolin-3-yl)methanol;
(4-fluorophenyl)(4-(4-fluorophenyl)-1-((5-methyl-1H-pyrazol-3-yl)amino)isoquinolin-3-yl)methyl formate;
(4-fluorophenyl)(4-(2-methoxyethoxy)-1-((5-methyl-1H-pyrazol-3-yl)amino)isoquinolin-3-yl)methanone;
3-((4-fluorophenyl)sulfinyl)-1-(1H-pyrazol-4-yl)isoquinoline;
3-((4-fluorophenyl)sulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)isoquinolin-1-amine;
3-((4-fluorophenyl)sulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-4-nitroisoquinolin-1-amine;
3-((4-fluorophenyl)sulfonyl)-N-(1H-pyrazol-3-yl)isoquinolin-1-amine;
3-((4-fluorophenyl)sulfonyl)-N-(5-methoxy-1H-pyrazol-3-yl)isoquinolin-1-amine;
N-(3-((4-fluorophenyl)sulfonyl)isoquinolin-1-yl)-5-methylthiazol-2-amine;
N-(3-((4-fluorophenyl)sulfonyl)isoquinolin-1-yl)thiazol-2-amine;
N-(3-((4-fluorophenyl)sulfonyl)isoquinolin-1-yl)oxazol-2-amine;
3-((3-((4-fluorophenyl)sulfonyl)isoquinolin-1-yl)amino)-1H-pyrazol-5-ol;
N-(3-((4-fluorophenyl)sulfonyl)isoquinolin-1-yl)-1,2,4-thiadiazol-5-amine;
3-((4-fluorophenyl)sulfonyl)-N-(1-methyl-1H-imidazol-4-yl)isoquinolin-1-amine;
3-((4-fluorophenyl)sulfonyl)-N-(1-methyl-d3-1H-imidazol-4-yl)isoquinolin-1-amine;
N-(1-ethyl-1H-imidazol-4-yl)-3-((4-fluorophenyl)sulfonyl)isoquinolin-1-amine; and
5-bromo-3-((4-fluorophenyl)sulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)isoquinolin-1-amine;
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 16 (depends on 1)

A method for treatment of a JAK modulated disease comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 17 (depends on 1)

A method for treatment of a JAK2 modulated disease comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 18 (depends on 17)

The method of claim 17, wherein JAK2 is wild type or mutant JAK2.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disease is cancer, myeloproliferative disorder, inflammation or autoimmune disease.

### Claim 20 (depends on 19)

The method of claim 19, further comprising administering a second pharmaceutical agent selected from anti-proliferative agent, anti-inflammatory agent, immunomodulatory agent and immunosuppressive agent.

### Claim at position 21

21-22. (canceled)
